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Abstract
Background: The endothelial PAS domain protein 1 (EPAS1) activates genes that are involved in erythropoiesis and
angiogenesis, thus favoring a better delivery of oxygen to the tissues and is a plausible candidate to influence
athletic performance. Using innovative statistical methods we compared genotype distributions and interactions of
EPAS1 SNPs rs1867785, rs11689011, rs895436, rs4035887 and rs1867782 between sprint/power athletes (n = 338),
endurance athletes (n = 254), and controls (603) in Polish and Russian samples. We also examined the association
between these SNPs and the athletes’ competition level (‘elite’ and ‘sub-elite’ level). Genotyping was performed by
either Real-Time PCR or by Single-Base Extension (SBE) method.
Results: In the pooled cohort of Polish and Russian athletes, 1) rs1867785 was associated with sprint/power athletic
status; the AA genotype in rs1867785 was underrepresented in the sprint/power athletes, 2) rs11689011 was also
associated with sprint/power athletic status; the TT genotype in rs11689011 was underrepresented sprint/power
athletes, and 3) the interaction between rs1867785, rs11689011, and rs4035887 was associated with sprint/power
athletic performance; the combinations of the AA genotype in rs4035887 with either the AG or GG genotypes in
rs1867785, or with the CT or CC genotypes in rs11689011, were underrepresented in two cohorts of sprint/power
athletes.
Conclusions: Based on the unique statistical model rs1867785/rs11689011 are strong predictors of sprint/power
athletic status, and the interaction between rs1867785, rs11689011, and rs4035887 might contribute to success in
sprint/power athletic performance.
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Background
Maximal oxygen uptake (VO2max) refers to the highest
rate at which oxygen can be consumed by the body dur-
ing intense exercise [1], and is, among other factors, an
important predictor of elite endurance performance [2].
Studies have shown that the changes in VO2max follow-
ing exercise training vary markedly between individuals
and that ~ 50% of the variance can be explained by
genetic factors [3]. Over the last two decades, many Sin-
gle Nucleotide Polymorphisms (SNPs) have been sug-
gested to influence elite performance and the variability
in VO2max increase following exercise training [4]. While
most of these SNPs were discovered using the candidate
gene approach [5], a more comprehensive, genome-wide
linkage approach has identified a genomic region on
chromosome 2 that is associated with the VO2max training
response. The endothelial PAS domain protein 1 (EPAS1)
gene was one of the four genes in this region responsible
for this linkage [6].
EPAS1 is a transcription factor playing a key role in
the Hypoxia Inducible Factor (HIF) pathway in blood,
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which is responsible for activating gene expression in re-
sponse to hypoxia [7]. In normal oxygen conditions, EPAS1
is quickly degraded in the cytoplasm. However, when
oxygen levels drop, EPAS1 becomes stabilized, translocates
to the nucleus and activates genes that are involved in
erythropoiesis (e.g. erythropoietin), and angiogenesis
(e.g., vascular endothelial growth factor), thus favoring
a better delivery of oxygen to the tissues [8]. Delivery
of oxygen to skeletal muscles during endurance exercise is
viewed a factor limiting VO2max [1]. Therefore, as a hypoxia
detector and as an activator of improved oxygen deliv-
ery to the active tissues, EPAS1 is a plausible candidate
to influence endurance performance.
EPAS1 SNPs have been previously associated with
blood parameters, such as alterations in erythropoietin,
hemoglobin and hematocrit [9-11], that are important
for success in athletic performance. For instance, Tibetans
with the TT genotype in registered SNP (rs) 11689011 had
lower hemoglobin concentration compared with their TC
counterparts [9]. However, to date, only one study has
examined a possible link between SNPs within EPAS1
and elite athletic performance [12]. This study looked
at SNPs and haplotypes within EPAS1 in elite Australian
athletes, stratified to two groups participating in middle-
distance (from 50 s to 10 min, n = 242), and long-distance
(from ~2 to 10 h, n = 151) events. These groups were
compared to a non-athletic control group. The T allele in
rs11689011 and the G allele in rs1867785, two SNPs lo-
cated in the first intron of EPAS1, were overrepresented in
the group of endurance athletes compared with controls
[12]. Furthermore, in the same study, two haplotypes in-
volving rs1867785, rs11689011, rs895436 and rs4035887
were associated with elite endurance performance. While
haplotype G (A-T-G-G) was overrepresented in elite
endurance athletes, haplotype F (G-C-C-G) was underrep-
resented in elite endurance athletes compared to controls
[12]. Despite these positive findings, and the strong
biological rational behind investigating EPAS1 in relation
to elite endurance performance, this is the only genetic
association study showing that EPAS1 SNPs impact
performance, and the sprinters consisting primarily of
100–400 m track runners and sprint cyclists were excluded
from the analysis. Replication studies are therefore needed
to confirm this association, particularly in different popula-
tions, and with a larger sample size [13].
Therefore, the aim of this study was to compare
genotype distributions and interactions of the EPAS1
SNPs rs1867785, rs11689011, rs895436, rs4035887 and
rs1867782 between sprint/power athletes, endurance
athletes, and controls in Polish and Russian cohorts.
We also examined the association between the EPAS1
SNPs and athletic status according to the athletes’ level
of competition (‘elite’ and ‘sub-elite’ level). In light of the re-
lationship previously observed between endurance-related
phenotypes and SNPs in the EPAS1, we hypothesized
that EPAS1 SNPs would be associated with elite endurance
performance compared to controls and sprint/power
athletes. We did not have specific directional hypoth-
eses for rs895436, rs4035887 and rs1867782 as these
SNPs have not previously been associated with any per-
formance and/or endurance-related phenotypes. We did
not have any directional hypothesis for rs11689011 ei-
ther, due to the conflicting results reported for this SNP
(the T allele in rs11689011 was associated with endurance
athletic status in elite Australians on one hand, and with
lower hemoglobin concentrations in Tibetans, on the
other hand) [9,12]. However, in line with the findings of
Henderson et al. [12] we did expect the rs1867785 G allele
to be associated with elite endurance performance. Finally,
we did not have any directional hypotheses for any of the
SNPs in relation to sprint/power performance.
Methods
The study was approved by the Pomeranian Medical
University Ethics Committee, Poland, and the Ural State
University of Physical Culture, Russia, and written in-
formed consent was obtained from each participant.
The study complied with the guidelines set out in the
Declaration of Helsinki and the ethics policy of the
Szczecin University [14].
Participants
The athletes and controls were all European Caucasians.
The athletes were categorized as either endurance athletes
or sprint/power athletes as determined by the distance,
duration and energy requirements of their event/sport. All
athletes were ranked in the top 10 nationally in their sport
discipline and grouped as being either ‘elite-level’ or ‘sub-
elite’ based on their best personal performance. Those in
the elite group had participated in international competi-
tions such as World and European Championships, and/
or Olympic Games, whereas those in the sub-elite group
had participated in national competitions only. Details on
the number of participants in the elite and sub-elite group
are presented in Table 1.
Polish sample
The sample comprised 198 Polish athletes (all men; mean
age ± SD, 28 ± 4.4 y), including 92 elite and sub-elite
sprint/power athletes and 106 elite and sub-elite endur-
ance athletes, as well as 428 healthy, unrelated, sedentary
controls (all male students of the University of Szczecin;
mean age ± SD, 20.8 ± 1.2 y).
Russian sample
The Russian sample comprised 394 athletes (287 men and
107 women; mean age ± SD, 27.8 ± 9.7 y), including 246
elite and sub-elite sprint/power athletes and 148 elite and
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sub-elite endurance athletes, as well as 175 healthy un-
related sedentary controls (104 men and 44 women, all
students or employees of the Ural State University of
Physical Culture; mean age ± SD, 30.2 ± 10.7 y). The de-
scription of the Polish and the Russian athletes according
to their event/sport is summarized in Table 1.
Genotyping
Polish sample
Genomic DNA was isolated from buccal epithelium
using GenElute Mammalian Genomic DNA Miniprep
Kit (Sigma, Hamburg, Germany) according to the manufac-
turer’s instructions. All genetic analyses were performed at
the Molecular Biology and Biotechnology Center, Faculty of
Biology, University of Szczecin. All samples were genotyped
in duplicate using allelic discrimination assays with Taqman®
probes (Applied Biosystems, Carlsbad, California, USA)
on a CFX96 Touch™ Real-Time PCR Detection System
(Bio-Rad, Hercules, California, USA). To discriminate
EPAS1 rs1867782, rs1867785, rs11689011, rs895436
and rs4035887 alleles, TaqMan® Pre-Designed SNP
Genotyping Assays were used (assay IDs: C__11639978_1_,
C__11639984_10, C___2148918_10, C___2148915_10,
C___2162989_10, respectively), including appropriate
primers and fluorescently labeled (FAM and VIC) MGB™
probes to detect the alleles. Genotypes were assigned using
all of the data from the study simultaneously.
Russian sample
Genomic DNA was isolated from buccal epithelium or
peripheral blood, during the years 2011–2013, using the
Diatom™ DNA Prep kit (Cat. # D 1025, IsoGene Lab Ltd,
Russia). Genotyping of five selected SNPs was performed
by Single-Base Extension (SBE) method. The sequence
surrounding each SNP was obtained from the Genome
Reference Consortium Human genome build 37 assembly
from the Ensembl Project [15]. The Primer3web software
v. 4.0.0 [16] was used for designing the PCR primers. PCR
product range was 109–173 bp. SBE primers to detect
rs895436, rs11689011, rs1867782, and rs1867785 were
designed to anneal on the positive strand immediately
adjacent to the single nucleotide variation sites. SBE pri-
mer for detection of rs4035887 was designed to anneal
on the negative strand. To avoid any non-specific
amplification and extension products, all primers were
BLASTed against human genome reference sequence.
Sets of preselected PCR primer pairs and SBE primers
were screened for potential cross-reactivity by using
AutoDimer software.
Multiplex PCR was performed in a volume of 15 μL
containing 1 × PCR buffer, 1.0 mM MgCl2, 0.2 mM
dNTPs, 0.7 μM of each primer (5 pairs), 1 unit SmarTaq
DNA polymerase (Dialat Ltd, Russia) and 5 ng of tem-
plate DNA. Thermal cycler conditions were: 95°C for
30 s, 30 cycles of 95°C for 45 s, 60°C for 45 s, 72°C for
60 sec and finally 10 min at 72°C in GeneAmp® PCR
System 9700 (Applied Biosystems). Multiplex PCR prod-
ucts were checked for quality and yield by running 3 μl in
2% agarose-TBE gels. 5 μL of PCR products were cleaned
with 1 unit of FastAP Thermosensitive Alkaline Phosphatase
(TAP) and 10 units of Exonuclease I (both enzymes from
Fermentas). Multiplex SBE reaction was performed by using
SNaPshot® Multiplex Kit (Applied Biosystems) in 5 μL
final volume, including 2.5 μL of SnaPshot Multiplex
Ready Reaction Mix, 1.0 μl pooled SBE primers and
Table 1 Athletes’ description
Polish athletes
(n = 196)
Russian athletes
(n = 394)
Elite
(n = 122)
Sub-elite
(n = 74)
Elite
(n = 131)
Sub-elite
(n = 263)
ENDURANCE
Rowing 33 8 7 7
Swimming 800 /1500 m 1 9 1 2
Cycling 11 3 0 0
Skating 3000/5000/10000 m 0 0 9 28
Cross-country skiing 2 0 2 62
Canoeing 9 1 0 0
Walking 0 0 5 9
Triathlon 2 3 0 0
Pentathlon 0 0 0 3
Decathlon 0 0 0 10
Marathon 0 6 0 0
Running 1500/3000/5000 m 7 11 1 2
Total 64 40 25 123
SPRINT/POWER
Skating 500/1000 m 1 0 6 17
Weightlifting 22 20 44 43
Long jump 5 3 1 0
Sprint 100/200/400 m 25 9 1 4
Swimming 50/100 m 2 0 5 12
Shooting 1 0 0 0
Pole vault 1 2 0 3
Javelin throw 1 0 0 0
Ice hockey 0 0 27 16
Taekwondo 0 0 3 5
Karate 0 0 5 3
Boxing 0 0 9 27
Wrestling 0 0 3 8
Ski cross freestyle 0 0 2 0
Snowboarding 0 0 0 1
Discus throw 0 0 0 1
Total 58 34 106 140
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1.5 μl of cleaned PCR product (the PCR sequences, the
SBE primers and their final concentration can be received
from the authors by request). The cycling conditions were
96°C 10 s, 50°C 5 s and 60°C 30 s, during 25 cycles in
GeneAmp® PCR System 9700 (Applied Biosystems). To
remove the unincorporated ddNTPs, the final product
was incubated with 1 unit of TAP (Fermentas). SnaPshot
products with GeneScan™ - 120 LIZ™ Size Standard (AB)
were diluted in Hi-Di™ Formamide (AB), denatured and
separated using an ABI PRISM 310 Genetic Analyzer (AB)
with a 47 cm length capillary and POP-4™ polymer (AB).
The SnaPshot® Primer Focus® Kit (AB) was used to analyze
individual SBE primers for their approximate sizing loca-
tions prior to performing the multiplex SBE reaction. Final
data were analyzed using the GeneMapper® Software v. 4.1
from Applied Biosystems following the software manual.
K562 DNA High Molecular Weight from Promega
Corp. (USA) served as positive control sample. Genetic
profile of K562 DNA was following: rs895436 – G/G,
rs11689011 – C/C, rs4035887 – T/T (for the negative
strand), rs1867785 – G/G, rs1867782 – C/C.
Each of the five PCR products (for the five different SNPs)
was formed from five different individuals, and was se-
quenced in separate reaction using BigDye® Terminator
v3.1 Cycle Sequencing Kit (Applied Biosystems) with
full coincidence of expected and observed sequences.
Sequencing was performed in a second laboratory
(Gordiz Ltd. Laboratory, Moscow, Russia), according
to latest recommendations [17].
Genotyping reliability across two laboratories
Genotyping was performed in duplicate in the same
Laboratory for accuracy. Two independent investigators
have called the genotyping score in each laboratory-100%
of the genotypes could be called. For the purpose of re-
sults reliability across two laboratories in two different
countries (Russia and Poland), different DNA samples
(one for each SNP, positive or negative controls) were
shipped from Russia to Poland and were genotyped by
TaqMan assays. The results of the genotyping were in
100% agreement across the two laboratories.
Statistical analysis
The genotype frequencies of all individual SNPs are
presented in Additional file 1. Before looking at both
the individual effects of the five EPAS1 SNPs and their
interactions, we selected the best genetic model for
each SNP. Then, SNP main effects, as well as SNP-SNP
interactions, were investigated using Multivariate Adaptive
Regression Splines (MARS), a nonparametric regression
method [18] that has been successfully applied for detecting
SNP-SNP interaction in several studies [19-22]. Finally, the
odds ratios (OR) of being either a sprint/power athlete or
an endurance athlete were calculated for each significant
SNP and significant interacting pairs of SNPs using the best
genetic model for each SNP. Details on the steps that have
been taken in the statistical analysis are shown in Figure 1.
Hardy–Weinberg equilibrium (HWE)
χ2 analysis was used to confirm if the control group, in
each of the two samples, met HWE expectations. HWE
was tested separately for each SNP.
Selection of the best genetic model for each SNP
Three inheritance models (dominant, recessive and additive
model) were assessed in the pooled cohorts of sprint/power
and endurance athletes (Polish and Russian) using the
Wald test in logistic regression models, and the best
model was selected based on the minimum p-value for each
SNP. The athletic status was divided into two categories
and encoded as a dummy variable: athlete (encoded as 1)
and control (encoded as 0). To adjust for multiple
comparisons, the false discovery rate was controlled
using the Benjamini and Hochberg correction [23]. For
consistency, the same genetic model was applied separately
in the Russian and Polish groups. All of the following
steps were performed once when comparing sprint/power
athletes with controls, and once again when comparing
endurance athletes with controls.
Analysis of SNP main effects and SNP-SNP interactions
Variable importance ranking for SNPs with strong Linkage
Disequilibrium (LD) has been shown to be biased in previ-
ous studies [24,25]. Therefore, LD in the 5 SNPs was exam-
ined using r2 [26], and the pairs of SNPs displaying a strong
LD (r2 > 0.8) were identified (Additional file 2). Only
rs11689011 and rs1867785 were in strong LD (r2 = 0.96).
Consequently, two MARS models, all corrected for sex,
were developed: one including rs11689011, rs895436,
rs4035887 and rs1867782, and another independent MARS
model including rs1867785, rs895436, rs4035887 and
rs1867782. For simplicity, we have only reported the
MARS model excluding rs11689011 in the Results section.
In MARS, the maximum number of basis functions
was set at 100, and the maximum degree of interaction
was set at 2. As MARS does not provide variable sig-
nificance using p-values, each covariate selected by
MARS was used as input into a logistic regression
model to determine its significance. All non-significant
covariates (p-value > 0.05) were excluded. To confirm
the significance of the covariates identified by the lo-
gistic regression, and to rank their importance, we used
the Bootstrap Inclusion Fraction (BIF) criterion [27]. We
obtained 10000 MARS models using 10000 random boot-
strap samples with replacement from the original data set.
Then, we calculated the proportion of times that a sig-
nificant variable appeared in the 10000 MARS models
and called this number the BIF. A variable which is
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approximately uncorrelated with others, and is only
significant at the chosen nominal α level in the MARS
model, is selected in about 50% of bootstrap samples. As
the p-value diminishes, the BIF tends toward 100%. Thus,
we only included covariates with a BIF > 50%.
For each significant covariate, the odds ratio (OR) of
being either a sprint/power or an endurance athlete,
depending on the genotype, was calculated. The 95%
confidence intervals (CI) were calculated by uncondi-
tional maximum likelihood estimation.
Results
In the pooled cohort of Russian and Polish controls,
genotype distributions for each of the five SNPs was in
agreement with HWE (p-value > 0.05).
Endurance athletes vs. controls
In the Russian sample, the MARS model excluding
rs11689011 yielded only one significant covariate, with
a BIF > 50%. An interaction between sex and rs1867785
was observed: the GA and GG genotypes in rs1867785
Figure 1 The five steps that were followed in the statistical analysis. MARS: Multivariate Adaptive Regression Splines, BIF: Bootstrap Inclusion
Fraction. Firstly, we selected the best genetic model for each SNP by testing three inheritance models (dominant, recessive and additive model)
for each SNP in the entire cohort of sprint/power athletes. Secondly, MARS was used to detect SNP main effects and SNP-SNP interactions
(rs1867785 and rs11689011 were used in two independent MARS models because of their strong linkage disequilibrium). Thirdly, the covariates
selected by MARS were input into a logistic regression model to determine their significance, and all covariates with p-value > 0.05 were
excluded. Fourthly, to validate the selected covariates, we repeated steps 2 and 3 on 10000 random samples with replacement from the original
dataset and calculated the how many times the selected covariates were significant in the 10000 random samples (BIF). All covariates with a
BIF < 50% were excluded. Fifthly, we calculated the odds ratio of the genotype combinations for each selected covariate to give a clear
biological interpretation.
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were underrepresented in women endurance athletes
(OR = 0.39, Table 2).
In the Polish sample, no covariate was selected in the
MARS model excluding rs11689011. When combining the
Russian and the Polish groups, no covariate was selected in
the MARS model excluding rs11689011.
Using the MARS model excluding rs1867785, the results
were almost identical to those of the MARS model exclud-
ing rs11689011 (Additional file 3: Table S2). However, in
the Polish sample one significant covariate was retained
with a BIF > 50%. The TT genotype in rs11689011 was
underrepresented in the cohort of endurance athletes
(OR = 0.49, Additional file 3: Table S2), especially in the
elite-level cohort compared to their sub-elite counterparts
(OR = 0.31, 95% confidence interval: 0.11-0.87, Table 3).
Sprint/power athletes vs. controls
In the Russian sample, the MARS model excluding
rs11689011 yielded two significant covariates (p-value < 0.05
in logistic regression); only one covariate, however, had
a BIF > 50% (Table 2). The AA genotype in rs1867785
was underrepresented in sprint/power athletes (OR = 0.47,
Figure 2), especially in the elite sprint/power athletes com-
pared to their sub-elite counterparts (OR = 0.35, 95% confi-
dence interval: 0.16-1.79, Table 3). In the Polish sample, no
covariates were selected in the MARS model (Table 2).
In the Russian and Polish samples combined, the MARS
model excluding rs11689011 yielded three significant co-
variates, two had a BIF > 50% (Table 2). The trend already
observed for rs1867785 in the Russian sprint/power group
was even stronger when combined with the Polish group
(BIF = 90.1%); the AA genotype in rs1867785 was under-
represented in sprint/power athletes (OR = 0.53, Figure 2),
especially in elite sprint/power athletes compared to
their sub-elite counterparts (OR = 0.41, 95% confidence
interval: 0.22-0.75). Furthermore, an interaction between
rs1867785 and rs4035887 was found; the combination of
the AA genotype in rs4035887 and the GA or GG geno-
type in rs1867785 was underrepresented in sprint/power
athletes (OR = 0.61, Table 2 and Figure 3). We note that the
genotype distribution of individual SNPs does not provide
information regarding the genotype distribution of their
combinations. For example, SNPA and SNPB are two SNPs
with alleles A/a and B/b, respectively. In this example allele
A is advantageous to performance, and allele B is also ad-
vantageous to performance but only when combined with
allele a. From this pattern, one would expect allele A to be
overrepresented in athletes, but the A + B combination to
be underrepresented in athletes.
Using the MARS model excluding rs1867785, the re-
sults were almost identical to those of the MARS model
excluding rs11689011 (Additional file 3: Table S2). How-
ever, the interaction between rs11689011 and rs4035887
in the Russian and Polish sample combined was not
significant (BIF = 49.5%).
Discussion
We have examined the genotype distribution and SNP-SNP
interaction of five SNPs in the first intron of the EPAS1
gene in European sprint/power and endurance athletes. We
initially hypothesised that these SNPs would be associated
with endurance athletic status. However, contrary to our
Table 2 Covariates identified in the MARS model excluding rs11689011
Covariate P-value1 BIF2 Odds Ratio
Endurance athletes vs. controls Russians rs1867785*sex 0.00022 61.7 Other combinations 1 (ref)
GA or GG in women 0.39 (0.24-0.65)
Polish
Russians + Polish
Sprint/power athletes vs. controls Russians rs4035887 0.0072 43.6 GA or GG 1 (ref)
AA 0.54 (0.34-0.88)
rs1867785 0.0017 78.3 GA or GG 1 (ref)
AA 0.47 (0.25-0.84)
Polish
Russians + Polish rs1867785 0.00016 90.1 GA + GG 1 (ref)
AA 0.53 (0.35-0.80)
rs4035887*rs1867785 0.00016 52.6 Other combinations 1 (ref)
AA at rs4035887 and 0.61 (0.45-0.85)
GA or GG at rs1867785
1P-value obtained by logistic regression.
2Bootstrap Inclusion Fraction calculated after running 10000 MARS models on 10000 bootstrap samples. A BIF of 90.1 indicates that the covariate of interest was
selected in 90.1% of the MARS models.
*denotes an interaction.
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Table 3 Genotype frequencies of the three Single Nucleotide Polymorphisms (SNPs) significantly associated with athletic performance
SNP Major/minor
allele
Model Genotypes Russians (Males + Females) Polish (Males)
Controls
(n = 175)
Endurance
athletes (n = 148)
Sprint/power
athletes (n = 246)
Controls
(n = 428)
Endurance
athletes (n = 106)
Sprint/power
athletes (n = 92)
rs11689011 T/C Recessive TC or CC 139 (79.4%) 119 (80.4%) 220 (89.4%) 353 (82.5%) 96 (90.6%) 82 (89.1%)
Elite 18 (72%) Elite 97 (91.5%) Elite 61 (93.8%) Elite 53 (91.4%)
Sub-elite 101 (82.1%) Sub-elite 123 (87.9%) Sub-elite 35 (85.4%) Sub-elite 29 (85.3%)
TT 36 (20.6%) 29 (19.6%) 26 (10.6%) 75 (17.5%) 10 (9.4%) 10 (10.9%)
Elite 7 (28%) Elite 9 (8.5%) Elite 4 (6.2%) Elite 5 (8.6%)
Sub-elite 22 (17.9%) Sub-elite 17 (12.1%) Sub-elite 6 (14.6%) Sub-elite 5 (14.7%)
rs4035887 G/A Dominant GA or GG 130 (74.3%) 119 (80.4%) 207 (84.1%) 297 (69.4%) 68 (64.2%) 62 (67.4%)
Elite 19 (76.0%) Elite 88 (83.0%) Elite 41 (63.1%) Elite 37 (63.8%)
Sub-elite 100 (81.3%) Sub-elite 119 (85.0%) Sub-elite 27 (65.9%) Sub-elite 25 (73.5%)
AA 45 (25.7%) 29 (19.6%) 39 (15.9%) 131 (30.6%) 38 (34.9%) 30 (32.6%)
Elite 6 (24.0%) Elite 18 (17.0%) Elite 24 (36.9%) Elite 21 (36.2%)
Sub-elite 23 (18.7%) Sub-elite 21 (15.0%) Sub-elite 14 (31.4%) Sub-elite 9 (26.5%)
rs1867785 A/G Recessive GA or GG 142 (81.1%) 122 (82.4%) 222 (90.2%) 356 (83.2%) 96 (90.6%) 82 (89.1%)
Elite 18 (72%) Elite 98 (92.5%) Elite 61 (93.8%) Elite 53 (91.4%)
Sub-elite 104 (84.6%) Sub-elite 124 (88.6%) Sub-elite 35 (85.4%) Sub-elite 29 (85.3%)
AA 33 (18.9%) 26 (17.6%) 24 (9.8%) 72 (16.8%) 10 (9.4%) 10 (10.9%)
Elite 7 (28%) Elite 8 (7.5%) Elite 4 (6.2%) Elite 5 (8.6%)
Sub-elite 19 (15.4%) Sub-elite 16 (11.4%) Sub-elite 6 (14.6%) Sub-elite 5 (14.7%)
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hypotheses our main findings were as follow: In the pooled
cohort of Polish and Russian athletes, 1) rs1867785 was
associated with sprint/power athletic status; the AA geno-
type in rs1867785 was underrepresented in sprint/power
athletes, 2) rs11689011 was also associated with sprint/
power athletic status; the TT genotype in rs11689011
was underrepresented in sprint/power athletes, and 3) the
interaction between rs1867785/rs11689011, and rs4035887
was associated with sprint/power athletic performance;
the combinations of the AA genotype in rs4035887 with
Figure 2 Genotype distributions of rs1867785 in the different groups. C: controls, E: endurance athletes, S/P: sprint/power athletes, **:
p < 0.01 in linear regression, ***: p < 0.001 in linear regression.
Figure 3 Interaction between rs11689011, rs4035887 and athletic status in the different groups. C: controls, E: endurance athletes, S/P:
sprint/power, ***: p < 0.001 in linear regression.
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either the GA or GG genotypes in rs1867785, or with
the CT or CC genotypes in rs11689011, were underrep-
resented in two cohorts of sprint/power athletes.
Compared with a previous study, the results of the
present study were unexpected. Henderson et al. [12] have
reported that the G allele in rs1867785 and the T allele in
rs11689011 were overrepresented in endurance athletes,
whereas we have observed that the G allele in rs1867785
was underrepresented (and the A allele was overrepresented)
in female Russian endurance athletes. Furthermore, in our
cohort, the T allele in rs11689011 was overrepresented in
female Russian endurance athletes, but underrepresented
in male Polish endurance athletes. A possible explanation
for the discrepancies between our study and the study
by Henderson et al. [12] is that our results regarding
rs11689011 and rs1867785 were sex-specific. Sex-specific
effects of SNPs are common in a wide range of phenotypes
such as waist-hip ratio [28], susceptibility to sport-related
injury [29], and increased muscle strength in response to
training [30]. We have also recently shown that PPARGC1A
rs4697425 was associated with elite female, but not with
male endurance running performance [31]. However, the
Polish endurance sample only comprised males, while the
Russian sample included both males and females. Interest-
ingly, the cohort in the study by Henderson et al. included
both males and females athletes, but sex was not investi-
gated as a covariate in their analysis [12].
Looking at each SNP separately, we found that rs1867785
and rs11689011 were associated with sprint/power per-
formance. However, these SNPs had very similar geno-
type distribution and are in strong LD (r2 = 0.964); the
A allele in rs1867785 segregates with the T allele in
rs11689011. Since previous studies have suggested that
SNPs with strong LD cannot be considered in the same
statistical model [24,25], and only one of these SNPs
might influence sprint/power performance, we have created
two MARS models and considered only one of the SNPs
in each model. As expected, the two MARS models
yielded almost identical results in all cohorts. However,
only rs11689011 was associated with endurance athletic
status in the Polish sample, while this was not the case for
rs1867785. This might be explained by the small difference
in genotype distribution in rs11689011 and rs1867785 in
the Polish control sample. In addition, the BIF obtained for
rs11689011, when comparing Polish endurance athletes
with controls, was not strong enough (65.4%), indicating a
correlation close to non-significance and sensitive to small
changes in genotype frequencies. The relatively large sam-
ple size generated from studying two cohorts of athletes in
the present study further reinforces the confidence in the
results of the present study.
Indeed, in the present study two European Caucasian
cohorts of athletes were grouped to explore the associ-
ation between SNPs in EPAS1 and athletic performance.
Our previous results indicated that combining two cohorts
of Caucasian athletes, especially when they are closely-
related, would be useful approach to detect an association
between SNPs and athletic status [13]. While previous stud-
ies combined athletes from different ancestries [32,33], here
we have studied athletes from closely-related European an-
cestries (e.g., Polish and Russians). This is reinforced by the
similarity in the genotype distribution in the control groups
(no more than 5% differences between the Russian and
Polish controls). Furthermore, studying two cohorts of
athletes has increased the sample size (overall 338 sprint/
power athletes and 254 endurance athletes), which further
strengthened our results and the likelihood that these
specific EPAS1 SNPs show a genuine association with
elite sprint/power performance.
An additional novel finding in the present study is that
the AA genotype in rs1867785, and the TT genotype in
rs11689011, is even more underrepresented in elite sprint/
power athletes compared with their sub-elite counterparts.
This has previously been demonstrated for the highly-
studied ACTN3 R577X SNP, as the 577XX genotype
was found in a lower frequency in elite sprint/power
athletes compared to their national-level counterparts
[34-36]. This observation indicates that while the EPAS1
SNPs are associated with the development of sprint/power
ability, they might be even more important in the de-
velopment of world-class sprint/power ability. This
finding, along with all the other findings in the present
study, was obtained using the Bootstrap Inclusion Fractions
(BIF) statistical method, which as far as we are aware of,
has never been used in sports genomics.
The BIF analysis is a useful technique for investigating
variations among selected models in samples drawn at
random with replacement. Such samples mimic datasets
that are structurally similar to that under study and that
could plausibly have arisen instead [37]. Initially designed
to test the stability of multivariable models, this non-
parametric method allowed us to test whether the
EPAS1 SNPs selected by MARS were sensitive to small
changes in the data, and confirm that they were unlikely
to be false positives. Also, this method allowed us to
see the relative importance of the different variables;
while rs1867785 and rs11689011 showed very strong
main effects in sprint/power athletes, their interaction
with rs4035887 was of smaller importance.
We have also shown that several SNPs within EPAS1 are
associated with endurance athletic status, in a sex-specific
manner. The TT genotype in rs11689011 was underrepre-
sented in the cohort of Polish endurance athletes. However,
this association was demonstrated only when either the
Polish or the Russian groups were analysed separately, and
was abolished when the two cohorts were combined. We
argue that we cannot be certain that these positive findings
are not false positives, as they might be a limitation of the
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smaller sample size. On the other hand, our positive
findings regarding the association between the EPAS1
SNPs and sprint/power athletic status were found in the
combined cohort of sprint/power athletes, and the BIFs
that were calculated for rs11689011 and rs1867785 were
extremely high (90.1% for rs1867785, and 93.6% for
rs11689011). Furthermore, these associations were more
pronounced when the athletes’ level of competition was
considered.
This study is not without limitations. In case–control
studies, the relative proportions of controls and cases
impacts the sample size required to detect an association
with a given power and significance level. In the present
study, with similar genotype distributions in Russians
and Polish, to detect an association with the same effect
size, at the same power and significance level, we would
require a larger sample size in the Russian population.
We acknowledge that the difference in numbers of athletes
and controls in our study might therefore contribute to our
results and the lack of replication in both athlete groups.
However, in any association study with elite athletes it is a
challenge to increase the sample size due to the very low
number of elite athletes available to study.
Finally, in previous reports EPAS1 SNPs have demon-
strated an association with performance-related blood pa-
rameters (e.g., alterations in erythropoietin, hemoglobin
and hematocrit) [9-11], and elite endurance performance
[12], in humans. However, is has also been shown that
EPAS1 deficient mice have greater oxidative stress and an
impaired response to oxidative stress [38]. A reduction in
hematocrit levels and a global decrease in peripheral blood
counts have also been observed in EPAS1-null mice [39].
Although no specific SNPs were tested in the mice model,
these studies illustrate the potential importance of the
EPAS1 gene in athletic-related phenotypes.
Conclusion
We found an association between EPAS1 rs1867785 and
EPAS1 rs11689011 and sprint/power athletic status, and
an interaction between rs1867785/11689011 and rs4035887
and sprint/power athletic status in two cohorts of closely-
related European athletes. Based on the statistical model
used either rs1867785 or rs11689011 are related to sprint/
power athletic status. The association between rs1867785
and sprint/power athletic status is in line with a previous
study in Australian athletes [12]. Unlike the vast number of
investigations into the genetics of endurance performance,
the genetic influence on elite sprint/power performance has
received limited attention, and only a few studies have char-
acterized the associations between genetic variants and elite
sprint/power performance. Most studies to date have re-
cruited only one cohort of athletes and were therefore ham-
pered by insufficient sample size. In the present study, we
have combined two cohorts of athletes and used innovative
statistical methods, which provide confidence in our results.
Functional studies directly demonstrating cause and effect,
or providing any proposed cellular or molecular mecha-
nisms to explain the association, are needed to extend and
validate these findings.
Additional files
Additional file 1: Genotype frequencies of the five investigated
Single Nucleotide Polymorphisms (SNPs).
Additional file 2: Linkage disequilibrium (LD) map of the five
investigated SNPs in EPAS1. The upper horizontal line represents the
strand of chromosome 2 containing EPAS1 and all five investigated SNPs.
The triangle below indicates the pairwise LD (r2) between the five SNPs.
Each SNP corresponds to a diagonal of this triangle, and the intersection
of two diagonals contains the value of LD for the corresponding SNP
pair. The colour within the squares represents the strength of the linkage
between each pair. Of all possible pairs of SNPs, only rs1867785 and
rs11689011 are in strong LD (red colour).
Additional file 3: Table S2. Covariates identified in the different
MARS models.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
SV and NE have made substantial contributions to conception and design,
analysis and interpretation of data, and have been involved in drafting the
manuscript or revising it critically for important intellectual content. PC and
VPP conceived the study, participated in its design and coordination and
helped drafting the manuscript. DAA and LS carried out the genetic studies
and participated in its design and its data collection. BFV, VAS, AMK and MS
carried out the genetic studies and participated in its design. ZJ carried out
the molecular genetic studies. DJB has been involved in drafting the
manuscript and revising it critically for important intellectual content. All
authors read and approved the final manuscript.
Acknowledgements
This study was supported by the Ministry of Sport of the Russian Federation,
and Gordiz Ltd (Moscow, Russia).
Author details
1Institute of Sport, Exercise and Active Living (ISEAL), Victoria University,
Melbourne, Australia. 2Department of Tourism and Recreation, Academy of
Physical Education and Sport, Gdansk, Poland. 3Ural State University of
Physical Culture, Chelyabinsk, Russia. 4Faculty of Physical Culture and Health
Promotion, University of Szczecin, Szczecin, Poland. 5Cell Biology
Department, Faculty of Biology, University of Szczecin, Szczecin, Poland.
6Murdoch Childrens Research Institute, The Royal Children’s Hospital,
Melbourne, Australia.
Received: 19 December 2013 Accepted: 7 May 2014
Published: 18 May 2014
References
1. Bassett DR, Howley ET: Limiting factors for maximum oxygen uptake and
determinants of endurance performance. Med Sci Sports Exerc 2000,
32:70–84.
2. Bentley DJ, Newell J, Bishop D: Incremental exercise test design and
analysis: implications for performance diagnostics in endurance athletes.
Sports Med 2007, 37:575–586.
3. Bouchard C, An P, Rice T, Skinner JS, Wilmore JH, Gagnon J, Pérusse L, Leon
AS, Rao DC: Familial aggregation of VO2max response to exercise
training: results from the HERITAGE Family Study. J Appl Physiol 1999,
87:1003–1008.
4. Eynon N, Ruiz JR, Oliveira J, Duarte JA, Birk R, Lucia A: Genes and elite
athletes: a roadmap for future research. J Physiol 2011, 589:3063–3070.
Voisin et al. BMC Genomics 2014, 15:382 Page 10 of 11
http://www.biomedcentral.com/1471-2164/15/382
5. Wang G, Padmanabhan S, Wolfarth B, Fuku N, Lucia A, Ahmetov II, Cieszczyk
P, Collins M, Eynon N, Klissouras V, Williams A, Pitsiladis Y: Genomics of elite
sporting performance: what little we know and necessary advances.
Adv Genet 2013, 84:123–149.
6. Bouchard C, Rankinen T, Chagnon YC, Rice T, Pérusse L, Gagnon J, Borecki I,
An P, Leon AS, Skinner JS, Wilmore JH, Province M, Rao DC: Genomic scan
for maximal oxygen uptake and its response to training in the HERITAGE
family study. J Appl Physiol 2000, 88:551–559.
7. Patel SA, Simon MC: Biology of hypoxia-inducible factor-2alpha in
development and disease. Cell Death Differ 2008, 15:628–634.
8. Ke Q, Costa M: Hypoxia-inducible factor-1 (HIF-1). Mol Pharmacol 2006,
70:1469–1480.
9. Beall CM, Cavalleri GL, Deng L, Elston RC, Gao Y, Knight J, Li C, Li JC, Liang
Y, McCormack M, Montgomery HE, Pan H, Robbins PA, Shianna KV, Tam SC,
Tsering N, Veeramah KR, Wang W, Wangdui P, Weale ME, Xu Y, Xu Z, Yang
L, Zaman MJ, Zeng C, Zhang L, Zhang X, Zhaxi P, Zheng YT: Natural
selection on EPAS1 (HIF2alpha) associated with low hemoglobin
concentration in Tibetan highlanders. Proc Natl Acad Sci U S A 2010,
107:11459–11464.
10. Gale DP, Harten SK, Reid CDL, Tuddenham EGD, Maxwell PH: Autosomal
dominant erythrocytosis and pulmonary arterial hypertension associated
with an activating HIF2α mutation. Blood 2008, 112:919–921.
11. Percy MJ: Familial erythrocytosis arising from a gain-of-function mutation
in the HIF2A gene of the oxygen sensing pathway. Ulster Med J 2008,
77:86–88.
12. Henderson J, Withford-Cave JM, Duffy DL, Cole SJ, Sawyer NA, Gulbin JP,
Hahn A, Trent RJ, Yu B: The EPAS1 gene influences the aerobic-anaerobic
contribution in elite endurance athletes. Hum Genet 2005, 118:416–423.
13. Eynon N, Hanson ED, Lucia A, Houweling PJ, Garton F, North KN, Bishop DJ:
Genes for elite power and sprint performance: ACTN3 leads the way.
Sports Med 2013, 43:803–817.
14. Kruk J: Good scientific practice and ethical principles in scientific
research and higher education. Cent Eur J Sports Sci Med 2013, 1:25–29.
15. The Ensembl Project. [www.ensembl.org]
16. Primer3web software v. 4.0.0. [http://bioinfo.ut.ee/primer3/]
17. Little J, Higgins JPT, Ioannidis JPA, Moher D, Gagnon F, von Elm E, Khoury
MJ, Cohen B, Davey-Smith G, Grimshaw J, Scheet P, Gwinn M, Williamson
RE, Zou GY, Hutchings K, Johnson CY, Tait V, Wiens M, Golding J, van Duijn
C, McLaughlin J, Paterson A, Wells G, Fortier I, Freedman M, Zecevic M, King
R, Infante-Rivard C, Stewart A, Birkett N: Strengthening the reporting of
genetic association studies (STREGA)–an extension of the STROBE
statement. Eur J Clin Invest 2009, 39:247–266.
18. Friedman JH: Multivariate adaptive regression splines. Ann Stat 1991,
19:1–141.
19. Lin H-Y, Chen YA, Tsai Y-Y, Qu X, Tseng T-S, Park JY: TRM: a powerful
two-stage machine learning approach for identifying SNP-SNP
interactions. Ann Hum Genet 2012, 76:53–62.
20. Zabaleta J, Su LJ, Lin H-Y, Sierra RA, Hall MC, Sartor AO, Clark PE, Hu JJ,
Ochoa AC: Cytokine genetic polymorphisms and prostate cancer
aggressiveness. Carcinogenesis 2009, 30:1358–1362.
21. Zabaleta J, Lin H-Y, Sierra RA, Hall MC, Clark PE, Sartor OA, Hu JJ, Ochoa AC:
Interactions of cytokine gene polymorphisms in prostate cancer risk.
Carcinogenesis 2008, 29:573–578.
22. Nonyane BAS, Foulkes AS: Application of two machine learning
algorithms to genetic association studies in the presence of covariates.
BMC Genet 2008, 9:71.
23. Benjamini Y, Hochberg Y: Controlling the false discovery rate: a practical
and powerful approach to multiple testing. J R Stat Soc Ser B Methodol
1995, 57:289–300 [B].
24. Goldstein BA, Hubbard AE, Cutler A, Barcellos LF: An application of random
forests to a genome-wide association dataset: methodological
considerations & new findings. BMC Genet 2010, 11:49.
25. Nicodemus KK, Malley JD: Predictor correlation impacts machine learning
algorithms: implications for genomic studies. Bioinformatics 2009,
25:1884–1890.
26. Johnson AD, Handsaker RE, Pulit SL, Nizzari MM, O’Donnell CJ, De Bakker
PIW: SNAP: a web-based tool for identification and annotation of proxy
SNPs using HapMap. Bioinforma Oxford Engl 2008, 24:2938–2939.
27. Royston P, Sauerbrei W: Using the Bootstrap to Explore Model Stability. In
Multivariable Model - Build A Pragmatic Approach to Regres Anal based Fract
Polynomials Model Contin Var. 1st edition. Chichester: Wiley; 2008:186–188.
28. Heid IIM, Jackson AUA, Randall J, Winkler T: Meta-analysis identifies 13
new loci associated with waist-hip ratio and reveals sexual dimorphism
in the genetic basis of fat distribution. Nat Genet 2010, 42:950.
29. Posthumus M, September AV, O’Cuinneagain D, van der Merwe W,
Schwellnus MP, Collins M: The COL5A1 gene is associated with increased
risk of anterior cruciate ligament ruptures in female participants.
Am J Sports Med 2009, 37:2234–2240.
30. Clarkson PM, Devaney JM, Gordish-Dressman H, Thompson PD, Hubal MJ,
Urso M, Price TB, Angelopoulos TJ, Gordon PM, Moyna NM, Pescatello LS,
Visich PS, Zoeller RF, Seip RL, Hoffman EP: ACTN3 genotype is associated
with increases in muscle strength in response to resistance training in
women. J Appl Physiol 2005, 99:154–163.
31. He Z-H, Hu Y, Li Y-C, Gong L-J, Cieszczyk P, Maciejewska-Karlowska A,
Leonska-Duniec A, Muniesa CA, Marín-Peiro M, Santiago C, Garatachea N,
Eynon N, Lucia A: PGC-related gene variants and elite endurance
athletic status in a Chinese cohort: a functional study. Scand J Med Sci
Sports in press.
32. Lucia A, Ruiz JR, Eynon N, Birk R, Bishop DJ, Gómez-Gallego F, Santiago C:
The rs12594956 polymorphism in the NRF-2 gene is associated with top-level
Spanish athlete’s performance status. J Sci Med Sport 2013, 16:135–139.
33. Ruiz JR, Eynon N, Meckel Y, Fiuza-Luces C, Santiago C, Gómez-Gallego F, Oliveira
J, Lucia A: GNB3 C825T polymorphism and elite athletic status: a replication
study with two ethnic groups. Int J Sports Med 2011, 32:151–153.
34. Eynon N, Ruiz JR, Femia P, Pushkarev VP, Cieszczyk P, Maciejewska-Karlowska
A, Sawczuk M, Dyatlov DA, Lekontsev EV, Kulikov LM, Birk R, Bishop DJ, Lucia
A: The ACTN3 R577X polymorphism across three groups of elite male
European athletes. PLoS One 2012, 7:e43132.
35. Yang N, MacArthur DG, Gulbin JP, Hahn AG, Beggs AH, Easteal S, North K:
ACTN3 genotype is associated with human elite athletic performance.
Am J Hum Genet 2003, 73:627–631.
36. Eynon N, Duarte JA, Oliveira J, Sagiv M, Yamin C, Meckel Y, Goldhammer E:
ACTN3 R577X polymorphism and Israeli top-level athletes. Int J Sports
Med 2009, 30:695–698.
37. Royston P, Sauerbrei W: Bootstrap assessment of the stability of
multivariable models. Stata J 2009, 9:547–570.
38. Scortegagna M, Ding K, Oktay Y, Gaur A, Thurmond F, Yan L-J, Marck BT,
Matsumoto AM, Shelton JM, Richardson JA, Bennett MJ, Garcia JA: Multiple
organ pathology, metabolic abnormalities and impaired homeostasis of
reactive oxygen species in Epas1−/− mice. Nat Genet 2003, 35:331–340.
39. Scortegagna M, Morris MA, Oktay Y, Bennett M, Garcia JA: The HIF family
member EPAS1/HIF-2alpha is required for normal hematopoiesis in
mice. Blood 2003, 102:1634–1640.
doi:10.1186/1471-2164-15-382
Cite this article as: Voisin et al.: EPAS1 gene variants are associated with
sprint/power athletic performance in two cohorts of European athletes.
BMC Genomics 2014 15:382.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Voisin et al. BMC Genomics 2014, 15:382 Page 11 of 11
http://www.biomedcentral.com/1471-2164/15/382
